Concord Gets the Green Light—USFDA Gives Dholka Site a Clean Bill of Health

Unknown Apr 02, 2026 650 Views

Concord Biotech Ltd (NSE: CONB.NS) has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility at Dholka, Gujarat, officially closing the recent inspection with a "No Action Indicated" (...